No Record Found
Sector
PharmaceuticalsOpen
₹831.95Prev. Close
₹829.35Turnover(Lac.)
₹923.82Day's High
₹860Day's Low
₹829.0552 Week's High
₹1,00052 Week's Low
₹555Book Value
₹278.28Face Value
₹1Mkt Cap (₹ Cr.)
8,163.58P/E
75.35EPS
11.08Divi. Yield
0.12USFDA conducted the Good Manufacturing Practices (GMP) inspection from October 24 to October 30 in 2024.
The certification came after a successful inspection by the Finnish Medicines Agency on behalf of EMA from March 10 to March 14, 2025
The partnership will work on a new biological entity (NBE) in the immuno-oncology field to better treat cancer.
Here are some of the stocks that may see significant price movement today: Aditya Birla Real Estate, Shilpa Medicare, Swiggy, etc.
No regulatory issues were raised by the USFDA at Unit-2 during the inspection, the company said in a regulatory filing.
Y/e 31 Mar( In .Cr) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 |
---|---|---|---|---|
Equity Capital | 9.78 | 8.68 | 8.68 | 8.68 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 2,690.81 | 2,134.04 | 2,108.9 | 2,056.99 |
Net Worth | 2,700.59 | 2,142.72 | 2,117.58 | 2,065.67 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Revenue | 830.31 | 805.97 | 741.29 | 733.67 |
yoy growth (%) | 3.02 | 8.72 | 1.03 | 8.56 |
Raw materials | -256.59 | -265.56 | -351.75 | -368.79 |
As % of sales | 30.9 | 32.95 | 47.45 | 50.26 |
Employee costs | -175.62 | -149.27 | -113.08 | -91.52 |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Profit before tax | 202.59 | 216.88 | 167.48 | 173.07 |
Depreciation | -40.84 | -34.95 | -32.77 | -26.65 |
Tax paid | -71.14 | -44.14 | -34.24 | -41.08 |
Working capital | -128.78 | 363.22 | 45.82 | 201.3 |
Other operating items |
Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 3.02 | 8.72 | 1.03 | 8.56 |
Op profit growth | -7.3 | 36.76 | -1.95 | 11.06 |
EBIT growth | -0.52 | 30.42 | -3.56 | 13.91 |
Net profit growth | -4.81 | 45.39 | 4.54 | 12.92 |
Particulars (Rupees in Crores.) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|---|
Gross Sales | 1,286.41 | 1,151.6 | 1,050.11 | 1,145.52 | 901.13 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 1,286.41 | 1,151.6 | 1,050.11 | 1,145.52 | 901.13 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 23.3 | 14.3 | 17.4 | 23.04 | 90.98 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,593.4 | 76.77 | 3,82,370.02 | 753.53 | 1 | 5,566.68 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,031.5 | 68.53 | 1,60,086.85 | 557 | 0.5 | 2,357 | 561.08 |
Cipla Ltd CIPLA | 1,563.8 | 24.45 | 1,26,308.5 | 1,303.13 | 1.02 | 4,501.66 | 397.38 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,591.7 | 61.17 | 1,21,608.14 | 551 | 0.17 | 2,567 | 224.34 |
Dr Reddys Laboratories Ltd DRREDDY | 1,304.2 | 15.79 | 1,08,845.31 | 2,961.2 | 0.61 | 7,788.7 | 345.75 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman (Non-Executive)
Omprakash Inani
Managing Director
Vishnukant Bhutada
Whole-time Director
Sharath Reddy Kalakota
Independent Director
Arvind Vasudeva
Independent Director
Hetal Gandhi
Company Sec. & Compli. Officer
Ritu Tiwary
Independent Director
Kamal K Sharma
Independent Director
Anita Bandyopadhyay
#12-6-214/A1,
Hyderabad Road,
Karnataka - 584135
Tel: 91-8532-238704
Website: http://www.vbshilpa.com
Email: info@vbshilpa.com
Karvy Selenium Tow-B,
31&32 Financial Dist, Nanakramguda,
Hyderabad-500032
Tel: 91-40-67162222
Website: www.kfintech.com
Email: einward.ris@kfintech.com
Summary
Shilpa Medicare Limited, formerly known as Shilpa Antibiotics Private Limited was incorporated as a Private Company on November 20, 1987. The Company changed the status to Public and the name of the C...
Read More
Reports by Shilpa Medicare Ltd
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.